A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Next Previous
Trial Profile

A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs Abametapir (Primary)
  • Indications Pediculosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Hatchtech

    • Most Recent Events

    • 14 Sep 2015 According to a Dr. Reddys Laboratories media release dated 14 September 2015, Hatchtech has filed an NDA with the US FDA for Xeglyze (abametapir) lotion.
    • 18 Mar 2015 According to a Hatchtech media release, a New Drug Application (NDA) will be submitted to the U.S. Food and Drug Administration (FDA) in the third quarter of 2015.
    • 18 Mar 2015 Results published in a Hatchtech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top